SUWANEE, GA, Jan. 02, 2018 (GLOBE NEWSWIRE) — SANUWAVE Health, Inc. (OTCQB: SNWV) has announced that the U.S. Food and Drug Administration (FDA) has issued its decision on the de novo submission for the dermaPACE® System.  Their decision, dated December 28, 2017, permits the marketing of the dermaPACE System as a Class II medical device used for the treatment of Diabetic […]